$25.46
0.421.68%
Ult. Agg.: Oct 26, 4:28 PM
Stoke Therapeutics (STOK) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.78 | $-0.81 | $-0.81 | $-0.58 |
| Actual | $-0.93 | $-0.79 | $-0.97 | $-0.65 |
| Surprise | -19.2% | +2.47% | -19.8% | -12.1% |
| Revenue | ||||
| Estimate | $5.4M | $5.2M | $5.2M | $6.0M |
| Actual | $9.3M | $6.2M | $1.4M | $10.6M |
| Surprise | +73.2% | +20.9% | -72.8% | +76.1% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.91 | $-0.96 | $-0.96 | $-0.88 |
| Revenue | ||||
| Consensus | $8.2M | $8.2M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $-0.93 | $-0.78 | -19.2 % |
| Q1 | May 7, 2026 | $-0.79 | $-0.81 | 2.47 % |
| Q4 | Mar 16, 2026 | $-0.97 | $-0.81 | -19.8 % |
| Q3 | Nov 4, 2025 | $-0.65 | $-0.58 | -12.1 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $9.32M | $5.38M | 73.2 % |
| Q1 | May 7, 2026 | $6.23M | $5.15M | 20.9 % |
| Q4 | Mar 16, 2026 | $1.40M | $5.15M | -72.8 % |
| Q3 | Nov 4, 2025 | $10.63M | $6.04M | 76.1 % |